An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration

  • Age-Related Macular Degeneration
Trial Status:

Recruiting

This trial runs in
Cities
  • Austin
Trial Identifier:

NCT05300724 2022-000046-15 GE43220

      Show trial locations

      The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      This is a multicenter prospective study in participants with intermediate age-related macular degeneration (iAMD). The main purpose of this study is to assess iAMD disease progression, by the timeline and rates of conversion for high-risk iAMD at baseline to more advanced AMD stages. The anticipated duration of the study will be approximately 5.5 years.

      Genentech, Inc. Sponsor
      NCT05300724 , GE43220 , 2022-000046-15 Trial Identifier
      No intervention Treatments
      Age-Related Macular Degeneration Condition
      Official Title

      A Multicenter, Prospective, Observational Study of the Progression of Intermediate Age-Related Macular Degeneration

      Eligibility Criteria

      All Gender
      ≥50 Years & ≤ 94 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • For women of childbearing potential, agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception, during the study for at least 28 days after the last fluorescein injection for the fluorescein angiography (FA) administration
      • High-risk intermediate AMD with more than one large drusen >125 µm and AMD pigmentary abnormalities in study eye with no evidence of prior or active exudative macular neovascularization (MNV) in either eye
      • nGA, iRORA, cRORA (on spectral domain optical coherence tomography [SD-OCT]), or GA secondary to AMD on color fundus photography (CFP) or fundus autofluorescence (FAF) in non-study eye
      Exclusion Criteria
      • Macular disease in either eye with subretinal deposits not typical of AMD
      • Pigmentary abnormalities of the retina in either eye not typical of AMD
      • Atrophy in either eye due to causes other than AMD
      • Any concurrent or history of ocular or intraocular condition in the study eye
      • Intraocular surgery, including cataract surgery, within 3 months prior to Day 1
      • Retinal tears or peripheral retinal breaks within 3 months prior to Day 1
      • Concurrent or history of laser photocoagulation or anti-VEGF treatment for exudative MNV, diabetic macular edema, retinal vein occlusion, or proliferative diabetic retinopathy
      • Previous participation in interventional clinical trials for GA or early stages of AMD, except for vitamins and minerals, regardless of the route of administration within the last 6 months, except for sham-arm participants
      • History of glaucoma-filtering surgery, corneal transplant, retinal pigment epithelium tear, retinal tear that involves the macula, retinal detachment
      • Uncontrolled progressive glaucoma
      • Moderate or severe non-proliferative diabetic retinopathy or proliferative diabetic retinopathy in either eye
      • History of recurrent infectious or inflammatory ocular disease in either eye

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now